Antimicrobial drug resistance rates for Mycoplasma pneumoniae was determined in clinical specimens and isolates obtained during 2011–2012 in Ontario, Canada. Of 91 M. pneumoniae drug-resistant specimens, 11 (12.1%) carried nucleotide mutations associated with macrolide resistance in the 23S rRNA gene. None of the M. pneumoniae specimens were resistant to fluoroquinolones or tetracyclines
An important role in the treatment regimens for Mycoplasma pneumoniae infections is played by macrol...
Mycoplasma pneumoniae remains a common cause of community acquired respiratory tract infections in a...
An important role in the treatment regimens for Mycoplasma pneumoniae infections is played by macrol...
Antimicrobial drug resistance rates for Mycoplasma pneumoniae was determined in clinical specimens a...
Background: The proportion of Mycoplasma pneumoniae isolates carrying point mutations in the 23S reg...
AbstractIn a total of 167 respiratory tract specimens from adult out-patients with confirmed Mycopla...
In Korea, Mycoplasma pneumoniae was detected in 255/2,089 respiratory specimens collected during 200...
The resistance rate of 67 Mycoplasma pneumoniae isolates from 356 ambulatory adult patients with res...
The development of macrolide resistance that occurred during 3 days of therapy with azithromycin to ...
Mycoplasma pneumoniae (MP) causes community-acquired pneumonia affecting mainly children, and tends ...
An important role in the treatment regimens for Mycoplasma pneumoniae infections is played by macrol...
Macrolide-resistant Mycoplasma pneumoniae (MRMP) is highly prevalent in Asia and is now being repo...
Mycoplasma pneumoniae is a frequent cause of human lower respiratory tract infections (LRTIs) for wh...
Mycoplasma pneumoniae is a major pathogen causing community-acquired pneumoniae (CAP), which is gene...
SummaryThe development of macrolide resistance that occurred during 3 days of therapy with azithromy...
An important role in the treatment regimens for Mycoplasma pneumoniae infections is played by macrol...
Mycoplasma pneumoniae remains a common cause of community acquired respiratory tract infections in a...
An important role in the treatment regimens for Mycoplasma pneumoniae infections is played by macrol...
Antimicrobial drug resistance rates for Mycoplasma pneumoniae was determined in clinical specimens a...
Background: The proportion of Mycoplasma pneumoniae isolates carrying point mutations in the 23S reg...
AbstractIn a total of 167 respiratory tract specimens from adult out-patients with confirmed Mycopla...
In Korea, Mycoplasma pneumoniae was detected in 255/2,089 respiratory specimens collected during 200...
The resistance rate of 67 Mycoplasma pneumoniae isolates from 356 ambulatory adult patients with res...
The development of macrolide resistance that occurred during 3 days of therapy with azithromycin to ...
Mycoplasma pneumoniae (MP) causes community-acquired pneumonia affecting mainly children, and tends ...
An important role in the treatment regimens for Mycoplasma pneumoniae infections is played by macrol...
Macrolide-resistant Mycoplasma pneumoniae (MRMP) is highly prevalent in Asia and is now being repo...
Mycoplasma pneumoniae is a frequent cause of human lower respiratory tract infections (LRTIs) for wh...
Mycoplasma pneumoniae is a major pathogen causing community-acquired pneumoniae (CAP), which is gene...
SummaryThe development of macrolide resistance that occurred during 3 days of therapy with azithromy...
An important role in the treatment regimens for Mycoplasma pneumoniae infections is played by macrol...
Mycoplasma pneumoniae remains a common cause of community acquired respiratory tract infections in a...
An important role in the treatment regimens for Mycoplasma pneumoniae infections is played by macrol...